In addition, a phase II single-arm clinical trial investigating anlotinib as a later-line therapy for HER2-negative breast cancer reported a disease control rate of 80.8% and a median PFS of 5.22 months (Hu et al., 2021). The gene discussed is ERBB2; the disease is breast carcinoma.